Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_2622_Библиотеки_им_академика_М_И_Перельмана
.pdf
Amyl oi dosis 77
4.12 Immune senescence
T-cell responses: decline, with reduced delayed-type hypersensitivity responses.
Antibody production: decreased for many exogenous antigens. Although
autoantibodies are frequently detected, autoimmune disease is less common.
Response to vaccination: reduced; 30% of healthy older people may not
develop protective immunity after inuenza vaccination.
Allergic disorders and transplant rejection: less common.
Susceptibility to infection: increased; community-acquired pneumonia by
threefold and urinary tract infection by 20-fold. Latent infections, including
tuberculosis and herpes zoster, may be reactivated.
Manifestations of inammation: may be absent, with lack of pyrexia or
leucocytosis.
Secondary immune deciency: common.
fever, arthralgia, myalgia, serositis and rashes. Attacks may be prolonged
for 1 week or more. During a typical attack, laboratory ndings include
neutrophilia, increased CRP and elevated IgA levels. The diagnosis can
be conrmed by low serum levels of the soluble type 1 TNF receptor and
by mutation screening of the TNFRSF1A gene. As in FMF, the major complication is amyloidosis, and regular screening for proteinuria is advised.
Acute episodes respond to systemic glucocorticoids. Therapy with IL-1
inhibitors, such as anakinra, can be effective in preventing attacks.
Cryopyrin-associated periodic syndrome (CAPS)
This disorder includes three phenotypes: familial cold auto-inammatory
syndrome, Muckle–Wells syndrome and neonatal-onset multisystem
inammatory disease. CAPS results from gain of function mutation of
the NLRP3 gene coding cryopyrin, which forms part of the inammasome. Defects lead to overproduction of IL-1, resulting in the inammatory
manifestations. Treatments are now targeted at the IL-1 pathway.
Amyloidosis
Amyloidosis is the name given to a group of acquired and hereditary disorders characterised by the extracellular deposition of insoluble proteins.
Pathophysiology
Amyloidosis is caused by deposits consisting of brils of the specic protein involved, linked to glycosaminoglycans, proteoglycans and serum
amyloid P. Protein accumulation may be localised or systemic, and the
clinical manifestations depend on the organ(s) affected. Amyloid diseases
are classied by the aetiology and type of protein deposited (Box 4.13).
Clinical features
The clinical presentation may be with nephrotic syndrome, cardiomyopathy or peripheral neuropathy. Amyloidosis should always be considered
as a potential diagnosis in patients with these disorders when the cause
is unclear.
Investigations
The diagnosis is established by biopsy, which may be of an affected
organ, rectum or subcutaneous fat. The pathognomonic histological feature is apple-green birefringence of amyloid deposits when stained with
Congo red dye and viewed under polarised light. Immunohistochemical
staining can identify the type of amyloid bril present. Quantitative scintigraphy with radiolabelled serum amyloid P is a valuable tool in determining the overall load and distribution of amyloid deposits.
Management
The aims of treatment are to support the function of affected organs and,
in acquired amyloidosis, to prevent further amyloid deposition through
treatment of the primary cause. When the latter is possible, regression of
existing amyloid deposits may occur.
4.13 Causes of amyloidosis
Disorder Pathological
Acquired systemic amyloidosis
Reactive (AA)
amyloidosis
basis
Increased
production of
serum amyloid
A as part of
prolonged or
recurrent acute
inammatory
response
Light chain
amyloidosis (AL)
Increased
production of
monoclonal light
chain
Dialysisassociated
(Aβ2M)
amyloidosis
Accumulation
of circulating
β2-microglobulin
due to failure of
renal catabolism
in kidney failure
Senile systemic
amyloidosis
Normal
transthyretin
protein
deposited in
tissues
Hereditary systemic amyloidosis
> 20 forms
of hereditary
systemic
amyloidosis
Production of
protein with
an abnormal
structure that
predisposes to
amyloid bril
formation. Most
commonly due
to mutations in
transthyretin
gene
Predisposing
conditions
Chronic infection
(tuberculosis,
bronchiectasis,
chronic abscess,
osteomyelitis)
Chronic
Other features
90% of patients
present with
non-selective
proteinuria
or nephrotic
syndrome
inammatory
diseases
(untreated
rheumatoid
arthritis, familial
Mediterranean
fever)
Monoclonal
gammopathies,
including
myeloma,
benign
gammopathies
and
plasmacytoma
Restrictive
cardiomyopathy,
peripheral and
autonomic
neuropathy,
carpal tunnel
syndrome,
proteinuria,
spontaneous
purpura, amyloid
nodules and
plaques
Macroglossia
occurs
rarely but is
pathognomonic
Prognosis is
poor
Renal dialysis Carpal tunnel
syndrome,
chronic
arthropathy and
pathological
fractures
secondary to
amyloid bone
cyst formation
Manifestations
occur 5–10
years after the
start of dialysis
Age > 70 years
Feature of
normal ageing
(affects > 90%
of 90-year-olds)
Usually
asymptomatic
Autosomal
dominant
inheritance
Peripheral and
autonomic
neuropathy,
cardiomyopathy
Renal
involvement
unusual
10% of gene
carriers are
asymptomatic
throughout life
4
78 C LIN I CA L IM M UN O LOG Y
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
Autoimmune disease
Autoimmunity can be dened as the presence of immune responses
against self-tissue. This may be a harmless phenomenon, identied
only by the presence of low-titre autoantibodies or autoreactive T cells.
However, if these responses cause signicant organ damage, autoimmune diseases occur. These are a major cause of chronic morbidity and
disability, affecting up to 1 in 30 adults at some point during life.
Pathophysiology
Autoimmune diseases result from the failure of immune tolerance, the process by which the immune system recognises and accepts self-tissue.
Central immune tolerance occurs during lymphocyte development, when
T and B lymphocytes that recognise self-antigens are eliminated before
they develop into fully immunocompetent cells. This process is most active
in fetal life but continues throughout life as immature lymphocytes are generated. Some autoreactive cells inevitably evade deletion and escape into
the circulation, however, and are controlled through peripheral tolerance
mechanisms. Peripheral immune tolerance mechanisms include the suppression of autoreactive cells by regulatory T cells; the generation of functional hyporesponsiveness (anergy) in lymphocytes that encounter antigen
in the absence of the co-stimulatory signals that accompany inammation;
and cell death by apoptosis. Autoimmune diseases develop when self-reactive lymphocytes escape from these tolerance mechanisms.
Multiple genetic and environmental factors contribute to the development of autoimmune disease. Autoimmune diseases are much more
common in women than in men, for reasons that remain unclear. Many
are associated with genetic variations in the HLA loci, reecting the importance of HLA genes in shaping lymphocyte responses. Other important
susceptibility genes include those determining cytokine activity, co-stimulation (the expression of second signals required for full T-cell activation; see
Figs. 4.7 and 4.8) and cell death. Many of the same gene variants under-
lie multiple autoimmune disorders, reecting their common pathogenesis
(Box 4.14). Even though some of these associations are the strongest that
have been identied in complex genetic diseases, they have very limited
predictive value and are generally not useful in determining management of
individual patients. Several environmental factors may be associated with
autoimmunity in genetically predisposed individuals, including infection,
cigarette smoking and hormone levels. The most widely studied of these is
infection, as occurs in acute rheumatic fever following streptococcal infection or reactive arthritis following bacterial infection. Several mechanisms
4.14 Association of specic gene polymorphisms with
autoimmune diseases
Gene Function Diseases
HLA complex Key determinants of
antigen presentation to
T cells
PTPN22 Regulation of T- and
B-cell receptor
signalling
CTLA4 Important co-
stimulatory molecule
that transmits inhibitory
signals to T cells
IL23R Cytokine-mediated
control of T cells
TNFRSF1A Control of tumour
necrosis factor network
ATG5 Autophagy Systemic lupus
Most autoimmune
diseases
Rheumatoid arthritis,
type 1 diabetes,
systemic lupus
erythematosus
Rheumatoid arthritis,
type 1 diabetes
Inammatory bowel
disease, psoriasis,
ankylosing spondylitis
Multiple sclerosis
erythematosus
have been invoked to explain the autoimmunity that occurs after an infectious trigger. These include cross-reactivity between proteins expressed
by the pathogen and the host (molecular mimicry), such as Guillain–Barré
syndrome and Campylobacter infection; release of sequestered antigens
from tissues that are damaged during infections that are not usually visible to the immune system; and production of inammatory cytokines that
overwhelm the normal control mechanisms that prevent bystander damage. Occasionally, autoimmune disease may be an adverse effect of drug
treatment. For example, metabolic products of the anaesthetic agent halothane can bind to liver enzymes, resulting in a structurally novel protein
that is recognised as a foreign antigen by the immune system. This can
provoke the development of autoantibodies and activated T cells, which
can cause hepatic necrosis.
Clinical features
The clinical presentation of autoimmune disease is highly variable.
Autoimmune diseases can be classied by organ involvement or by the
predominant mechanism responsible for tissue damage. The Gell and
Coombs classication of hypersensitivity is the most widely used, and
distinguishes four types of immune response that result in tissue damage
(Box 4.15).
Type I hypersensitivity is relevant in allergy but is not associated with
autoimmune disease.
Type II hypersensitivity causes injury to a single tissue or organ and
is mediated by specic autoantibodies.
Type III hypersensitivity results from deposition of immune complexes,
which initiates activation of the classical complement cascade, as well
as recruitment and activation of phagocytes and CD4+ lymphocytes.
The site of immune complex deposition is determined by the relative
amount of antibody, size of the immune complexes, nature of the
4.15 Gell and Coombs classication of hypersensitivity
diseases
Type Mechanism Example of
Type I
Immediate
hypersensitivity
Type II
Antibodymediated
IgE-mediated
mast cell
degranulation
Binding of
cytotoxic IgG or
IgM antibodies
to antigens on
cell surface
causes cell
disease in
response to
exogenous
agent
Allergic disease None described
ABO blood
transfusion
reaction
Hyperacute
transplant
rejection
killing
Type III
Immune
complexmediated
IgG or IgM
antibodies
bind soluble
antigen to
Serum sickness
Farmer's lung
form immune
complexes that
trigger classical
complement
pathway
activation
Type IV
Delayed type
Activated T
cells, and
phagocytes
Acute cellular
transplant
rejection
Nickel
hypersensitivity
Example of
autoimmune
disease
Autoimmune
haemolytic
anaemia
Idiopathic
thrombocytopenic
purpura
Goodpasture's
disease
Systemic lupus
erythematosus
Cryoglobulinaemia
Type 1 diabetes
Hashimoto's
thyroiditis
Au to im m un e d is ea se 79
antigen and local haemodynamics. Generalised deposition of immune
complexes gives rise to systemic diseases such as SLE.
Type IV hypersensitivity is mediated by activated T cells and mac-
rophages, which together cause tissue damage.
Investigations
Autoantibodies
Many autoantibodies have been identied and are used in the diagnosis
and monitoring of autoimmune diseases, as discussed elsewhere in this
book. Antibodies can be quantied either by titre (the maximum dilution
of the serum at which the antibody can be detected) or by concentra-
tion in standardised units using an enzyme-linked immunosorbent assay
(ELISA) in which the antigen is used to coat microtitre plates to which
the patient's serum is added (Fig. 4.13A). Immunoblotting (Fig. 4.13B)
can also be employed for autoantibody detection as well as qualitative
tests in which the pattern of immunouorescence staining is recorded
A
Antibodies bind to target
Wash
Target antigen
B
Detection of bound antibody Quantitate on plate reader
Target antigen
(Fig. 4.13C). Antibody testing can also be performed using Luminex
technology. In this case multiple test antigens are individually bound
to red and infra-red uorescently labelled polystyrene or paramagnetic
beads. Each antigen-coated bead is coated with a unique proportion of
red and infrared dyes. The patient sample is incubated with these beads
and if antibodies are present in the sample these will bind to the test antigens coating the beads. After washing to remove unbound antibodies,
a third uorescent dye is added and the sample is processed through a
dual laser Luminex analyser, which can detect the unique spectral signatures arising from beads coated with different test antigens allowing
detection of multiple antibodies present in a single patient sample.
Complement
Measurement of complement components can be useful in the evaluation of immune complex-mediated diseases. Classical complement
pathway activation leads to a decrease in circulating C4 levels and is
Wash
4
C
Nucleolar Homogenous
Speckled P-ANCA
Fig. 4.13 Autoantibody testing.
plates to which patient serum is added. If autoantibodies are present, these bind to the target antigen on the microtitre plate. The amount of bound antibody is quantitated
autoantibodies by immunoblotting. Test strips are coated with puried antigens in parallel lines. The strips are incubated with patient serum or plasma and controls. After
washing to remove unbound antibody, strips are incubated with enzyme-conjugated alkaline phosphatase-labelled anti-human IgG. After washing and addition of a chromogenic
substrate, an enzyme-mediated colour reaction develops. After a nal wash, the strips are dried and any observed banding pattern is scanned for band intensity against an
electronic template. The black bars on the strip separate the antigens being tested. Positive results are seen as vertical grey lines below the test antigen and the intensity
of staining corresponds to the concentration of antibody in the patient’s serum. The strength of staining is expressed both as a number and as a grade from + (weak) to +++
(strong). Note that all strips contain an internal quality control (marked as Ko or Co), to ensure the assay has worked. In the example shown, the patient sample was positive for
of indirect immunouorescence staining. In this assay, patient serum is added to cell substrate and a secondary antibody is added with a uorescent label to detect any bound
antibody. If antibodies are present, they are detected as bright green staining using a uorescence microscope. Different antinuclear antibody patterns may be seen in different
types of connective tissue disease using a HEp2 or HEp2000 (human epithelial cell line) as substrate (see Ch. 26). Immunouorescence can be undertaken using different
substrates, according to the autoantibody under investigation. An antinucleolar ANA can be seen in systemic sclerosis, a homogenous ANA can be seen in SLE and a speckled
ANA can be seen in SLE or Sjögren syndrome. In the context of small vessel vasculitis, the tissue substrate is ethanol-xed neutrophils. Two main staining patterns of anti-
neutrophil cytoplasmic antibodies (ANCA) are clinically relevant, cytoplasmic and perinuclear, seen in granulomatosis with polyangiitis and microspcopic polyangiitis (see Ch. 26),
the autoantibodies recognising proteinase 3 and myeloperoxidase respectively. (B and C, Nucleolar and Homogenous) Courtesy of Juliet Dunphy, Biomedical Scientist, Royal
United Hospital Bath, UK; (C, Speckled and P-ANCA) Courtesy of Mr Richard Brown, Clinical Scientist in Immunology, Southwest Pathology Services, UK
80 C LIN I CA L IM M UN O LOG Y
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
often also associated with decreased C3 levels. Serial measurement of
C3 and C4 can be helpful as a surrogate measure of disease activity in
conditions such as SLE.
Cryoglobulins
Cryoglobulins are antibodies that can be directed against other immunoglobulins, which form immune complexes that precipitate in the cold. They
can lead to type III hypersensitivity reactions, with typical clinical manifestations including purpuric rash, often of the lower extremities, arthralgia
and peripheral neuropathy. Cryoglobulins are classied into three types,
depending on the properties of the immunoglobulin involved (Box 4.16).
Testing for cryoglobulins requires the transport of a serum specimen to
the laboratory at 37°C. Cryoglobulins should not be confused with cold
agglutinins; the latter are autoantibodies specically directed against the I/i
antigen on the surface of red cells, which can cause intravascular haemolysis in the cold (p. 958).
Management
The management of autoimmune disease depends on the organ system involved and further details are provided elsewhere in this book. In
general, treatment of autoimmune diseases involves the use of glucocorticoids and immunosuppressive agents, which are increasingly used
in combination with biologic agents targeting disease-specic cytokines
and their receptors. Not all conditions require immune suppression, however. For example, the management of coeliac disease involves dietary
gluten withdrawal, while autoimmune hypothyroidism requires appropriate thyroxine supplementation.
Allergy
Allergic diseases are a common and increasing cause of illness, affecting
between 15% and 20% of the population at some time. They comprise a
range of disorders from mild to life-threatening and affect many organs.
Atopy is the tendency to produce an exaggerated IgE immune response
to otherwise harmless environmental substances, while an allergic disease can be dened as the clinical manifestation of this inappropriate IgE
immune response.
Pathophysiology
The immune system does not normally respond to the many environmental substances to which it is exposed on a daily basis. In allergic individuals, however, an initial exposure to a normally harmless exogenous
substance (known as an allergen) triggers the production of specic IgE
antibodies by activated B cells. These bind to high-afnity IgE receptors
on the surface of mast cells, a step that is not itself associated with clinical sequelae. However, re-exposure to the allergen binds to and crosslinks membrane-bound IgE, which activates the mast cells, releasing a
variety of vasoactive mediators (the early phase response; Fig. 4.14 and
see Chapter 9). This type I hypersensitivity reaction forms the basis of
an allergic reaction, which can range from sneezing and rhinorrhea to
anaphylaxis (Box 4.17). In some individuals, the early phase response
is followed by persistent activation of mast cells, manifest by ongoing
swelling and local inammation. This is known as the late phase reaction and is mediated by mast cell metabolites, basophils, eosinophils
and macrophages. Long-standing or recurrent allergic inammation may
give rise to a chronic inammatory response characterised by a complex
inltrate of macrophages, eosinophils and T lymphocytes, in addition to
mast cells and basophils. Once this has been established, inhibition of
mast cell mediators with antihistamines is clinically ineffective in isolation.
Mast cell activation may also be non-specically triggered through other
signals, such as neuropeptides, anaphylotoxins and bacterial peptides.
The increasing incidence of allergic diseases is largely unexplained
but one widely held theory is the ‘hygiene hypothesis’. This proposes
that infections in early life are critically important in maturation of the
immune response and bias the immune system against the development
of allergies; the high prevalence of allergic disease is the penalty for the
decreased exposure to infection that has resulted from improvements
in sanitation and health care. Genetic factors also contribute strongly to
the development of allergic diseases. A positive family history is common in patients with allergy, and genetic association studies have identied a wide variety of predisposing variants in genes controlling innate
immune responses, cytokine production, IgE levels and the ability of the
epithelial barrier to protect against environmental agents. The expression
of a genetic predisposition is complex; it is governed by environmental
factors, such as pollutants and cigarette smoke, and the incidence of
bacterial and viral infection.
4.16 Classication of cryoglobulins
Type I Type II Type III
Immunoglobulin (Ig) isotype and
specicity
Isolated monoclonal IgM paraprotein
with no particular specicity
Immune complexes formed by
monoclonal IgM paraprotein
directed towards constant region
Immune complexes formed by polyclonal
IgM or IgG directed towards constant region
of IgG
of IgG
Prevalence 25% 25% 50%
Disease association Lymphoproliferative disease,
especially Waldenström
macroglobulinaemia
Symptoms Hyperviscosity:
Raynaud's phenomenon
Acrocyanosis
Retinal vessel occlusion
Arterial and venous thrombosis
Infection, particularly hepatitis C;
lymphoproliferative disease
Small-vessel vasculitis:
Purpuric rash
Arthralgia
Neuropathy
Cutaneous ulceration,
Infection, particularly hepatitis C;
autoimmune disease, including rheumatoid
arthritis and systemic lupus erythematosus
Small-vessel vasculitis:
Purpuric rash, arthralgia
Cutaneous ulceration hepatosplenomegaly,
glomerulonephritis
Raynaud's phenomenon
hepatosplenomegaly,
glomerulonephritis, Raynaud's
phenomenon
Protein electrophoresis Monoclonal IgM paraprotein Monoclonal IgM paraprotein No monoclonal paraprotein
Rheumatoid factor Negative Strongly positive Strongly positive
Complement Usually normal Decreased C4 Decreased C4
Serum viscosity Raised Normal Normal
Allerg y 81
A
B
T and B cells
Allergen
T
B
T
B
B
B
B
IgE antibody
B
B C
IgE receptor
Fig. 4.14 Type I (immediate) hypersensitivity response.
mast cells. This cross-linking of the IgE triggers mast cell activation with release of vasoactive mediators.
4.17 Clinical manifestations of allergy
Dermatological
Urticaria
Atopic eczema if chronic
Respiratory
Asthma Atopic rhinitis
Ophthalmological
Allergic conjunctivitis
Gastrointestinal
Food allergy
Other
Anaphylaxis
Drug allergy
Allergic contact eczema
Angioedema
Allergy to insect venom
Clinical features
Common presentations of allergic disease are shown in Box 4.17. Those
that affect the respiratory system and skin are discussed in more detail
in Chapters 17 and 27, respectively. Here we focus on general principles
of the approach to the allergic patient and some specic allergies. The
management of acute anaphylaxis is discussed in Chapter 9
Insect venom allergy
Local non-IgE-mediated reactions to insect stings are common and may
cause extensive swelling around the site lasting up to 7 days. These
usually do not require specic treatment. Toxic reactions to venom after
multiple (50–100) simultaneous stings may mimic anaphylaxis. In addition, exposure to large amounts of insect venom frequently stimulates
the production of IgE antibodies, and thus may be followed by allergic
reactions to single stings. Allergic IgE-mediated reactions vary from mild
to life-threatening. Antigen-specic immunotherapy (desensitisation; see
below) with bee or wasp venom can reduce the incidence of recurrent
anaphylaxis from 50% to 60% to approximately 10%, but requires 3–5
years of treatment or more.
Peanut allergy
Peanut allergy is the most common food-related allergy. More than 50%
of patients present before the age of 3 years and some individuals react
to their rst known exposure to peanuts, thought to result from sensitisation to arachis oil in topical creams. Peanuts are ubiquitous in the
Western diet, and every year up to 25% of peanut-allergic individuals
experience a reaction as a result of inadvertent exposure.
Birch oral allergy syndrome
This syndrome is characterised by the combination of birch pollen hay
fever and local oral symptoms, including itch and angioedema, after contact with certain raw fruits, raw vegetables and nuts. Cooked fruits and
vegetables are tolerated without difculty. It is due to shared or crossreactive allergens that are destroyed by cooking or digestion, and can be
conrmed by skin-prick testing using fresh fruit. Severe allergic reactions
are unusual.
Diagnosis
When assessing a patient with a complaint of allergy, it is important to
identify what the patient means by the term, as up to 20% of the UK
population describe themselves as having a food allergy; in fact, less
than 1% have true allergy, as dened by an IgE-mediated hypersensitivity reaction conrmed on double-blind challenge. The nature of the
symptoms should be established and specic triggers identied, along
with the predictability of a reaction, and the time lag between exposure to
a potential allergen and onset of symptoms. An allergic reaction usually
occurs within minutes of exposure and provokes predictable, reproducible symptoms such as angioedema, urticaria and wheezing. Specic
enquiry should be made about other allergic symptoms, past and present, and about a family history of allergic disease. Potential allergens in
the home and workplace should be identied. A detailed drug history
should always be taken, including details of adherence to medication,
possible adverse effects and the use of over-the-counter or complementary therapies.
Investigations
Skin-prick tests
Skin-prick testing is a key investigation in the assessment of patients
suspected of having allergy. A droplet of diluted standardised allergen
is placed on the forearm and the skin is supercially punctured through
the droplet with a sterile lancet. Positive and negative control material must be included in the assessment. After 15 minutes, a positive
response is indicated by a local weal and are response 2 mm or more
larger than the negative control. A major advantage of skin-prick testing is that the patient can clearly see the results, which may be useful
in gaining adherence to avoidance measures. Disadvantages include
the remote risk of a severe allergic reaction, so resuscitation facilities
should be available. Results are unreliable in patients with extensive
skin disease. Antihistamines inhibit the magnitude of the response and
should be discontinued for at least 3 days before testing; low-dose glucocorticoids do not inuence test results. A number of other prescribed
medicines can also lead to false-negative results, including amitriptyline
and risperidone.
Mast cell
Histamine, tryptase and
vasoactive peptides
4
82 C LIN I CA L IM M UN O LOG Y
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
Specic IgE tests
An alternative to skin-prick testing is the quantitation of IgE directed
against the suspected allergen. The sensitivity and specicity of specic
IgE tests (previously known as radioallergosorbent tests, RAST) are lower
than those of skin-prick tests. However, IgE tests may be very useful if
skin testing is inappropriate, such as in patients taking antihistamines
or those with severe skin disease or dermatographism. They can also
be used to test for cross-reactivity – for example, with multiple insect
venoms, where component-resolved diagnostics, using recombinant
allergens, is now increasingly used rather than crude allergen extract.
Component resolved diagnostics (CRD) is a more recent development
in allergic investigation. CRD uses puried native or recombinant allergens to detect specic IgE directed against individual allergenic molecules. CRD can discriminate genuine sensitisation from sensitisation due
to cross reactivity and in some cases can be used in risk stratication. For
example, in patients with hazelnut allergy, the clinical features can be mild
and most consistent with the oral allergy syndrome rather than primary
nut allergy, in which case CRD may conrm specic IgE to Cor a1, a birch
pollen homologue, hence the association with the oral allergy syndrome,
whereas patients with primary hazelnut allergy positive for Cor a9 or Cor
a14 tend to have more severe allergy. Severity of reaction in peanut allergy
can also be associated with specic Ara h allergens, which are present in
peanuts. Such risk stratication can impact on patient management, for
example, identifying patients who may require an adrenaline auto-injector.
Supervised exposure to allergen
Tests involving supervised exposure to an allergen (allergen challenge)
are usually performed in specialist centres on carefully selected patients,
and include bronchial provocation testing, nasal challenge, and food or
drug challenge. These may be particularly useful in the investigation of
occupational asthma or food allergy. Patients can be considered for challenge testing when skin tests and/or IgE tests are negative, as they can
be helpful in ruling out allergic disease.
Mast cell tryptase
Measurement of serum mast cell tryptase is extremely useful in investigating a possible anaphylactic event. Ideally, measurements should be
made at the time of the reaction following appropriate resuscitation, and
3 hours and 24 hours later. The basis of the test is the fact that circulating levels of mast cell degranulation products rise dramatically to peak
1–2hours after a systemic allergic reaction. Tryptase is the most stable
of these and is easily measured in serum.
Serum total IgE
Serum total IgE measurements are not routinely indicated in the investigation of allergic disease, other than to aid in the interpretation of specic
IgE results, as false-positive specic IgEs are common in patients with
atopy, who often have a high total IgE level. Although atopy is the most
common cause of an elevated total IgE in developed countries, there
are many other causes, including parasitic and helminth infections, lymphoma, drug reactions and eosinophilic granulomatosis with polyangiitis
(previously known as Churg–Strauss vasculitis). Normal total IgE levels
do not exclude allergic disease.
Eosinophilia
Peripheral blood eosinophilia is common in atopic individuals but lacks
specicity. Eosinophilia of more than 20% or an absolute eosinophil count
over 1.5 ×10
eosinophilic granulomatosis with polyangiitis or parasitic infection.
9
/L should initiate a search for a non-atopic cause, such as
Management
Several approaches can be deployed in the management of allergic individuals, as discussed below.
Antihistamines
Antihistamines are useful in the management of allergy as they inhibit the
effects of histamine on tissue H
preparations are particularly useful for prophylaxis.
receptors. Long-acting, non-sedating
1
Glucocorticoids
These are highly effective in allergic disease, and if used topically, adverse
effects can be minimised.
Sodium cromoglicate
Sodium cromoglicate stabilises the mast cell membrane, inhibiting
release of vasoactive mediators. It is effective as a prophylactic agent
in asthma and allergic rhinitis but has no role in management of acute
attacks. It is poorly absorbed and therefore generally ineffective in the
management of food allergies.
Antigen-specic immunotherapy
This involves the sequential administration of increasing doses of allergen extract over a prolonged period of time. The mechanism of action
is not fully understood but it is highly effective in the prevention of insect
venom anaphylaxis and of allergic rhinitis secondary to grass pollen
allergy. The traditional route of administration is by subcutaneous injection, which carries a risk of anaphylaxis and should be performed only
in specialised centres. Sublingual immunotherapy is also increasingly
used. Clinical studies to date do not support the use of allergen immunotherapy for food hypersensitivity, although this is an area of active
investigation.
Omalizumab
Omalizumab is a monoclonal antibody directed against IgE; it inhibits the
binding of IgE to mast cells and basophils. It is licensed for treatment of
refractory chronic spontaneous urticaria and also for severe persistent
allergic asthma that has failed to respond to standard therapy. The dose
and frequency are determined by baseline IgE (measured before the start
of treatment) and body weight. It is under investigation for allergic rhinitis
but not yet approved for this indication.
Adrenaline (epinephrine)
Adrenaline given by injection in the form of a pre-loaded self-injectable device
can be life-saving in the acute management of anaphylaxis (see Ch. 9).
Angioedema
Angioedema is an episodic, localised, non-pitting swelling of submucous
or subcutaneous tissues.
Pathophysiology
The causes of angioedema are summarised in Box 4.18. It may be a
manifestation of allergy or non-allergic degranulation of mast cells in
response to drugs and toxins. In these conditions the main cause is mast
cell degranulation with release of histamine and other vasoactive mediators. In hereditary angioedema, the cause is C1 inhibitor deciency, which
leads to increased local release of bradykinin. Angiotensin-converting
enzyme (ACE) inhibitor-induced angioedema also occurs as the result of
increased bradykinin levels due to inhibition of its breakdown.
Clinical features
Angioedema is characterised by soft-tissue swelling that most frequently
affects the face (Fig. 4.15) but can also affect the extremities and genitalia. Involvement of the larynx or tongue may cause life-threatening
respiratory tract obstruction, and oedema of the intestinal mucosa may
cause abdominal pain and distension.
Avoidance of the allergen
This is indicated in all cases and should be rigorously attempted, with the
advice of specialist dietitians and occupational physicians as necessary.
Investigations
Differentiating the mechanism of angioedema is important in determining the most appropriate treatment. A clinical history of allergy or drug
4.18 Types of angioedema
Angioe dema 83
Allergic reaction to specic
trigger
Pathogenesis IgE-mediated degradation of
mast cells
Idiopathic angioedema Hereditary angioedema ACE-inhibitor associated
Non-IgE-mediated
degranulation of mast cells
C1 inhibitor deciency, with
resulting increased local
angioedema
Inhibition of breakdown of
bradykinin
bradykinin concentration
Key mediator Histamine Histamine Bradykinin Bradykinin
Prevalence Common Common Rare autosomal dominant
disorder
Clinical features Usually associated with
urticaria
History of other allergies
common
Follows exposure to specic
allergen, in food, animal
dander or insect venom
Usually associated with
urticaria
May be triggered by physical
stimuli such as heat, pressure
or exercise
Dermatographism common
Occasionally associated with
Not associated with urticaria
or other features of allergy
Does not cause anaphylaxis
May cause life-threatening
respiratory tract obstruction
Can cause severe abdominal
pain
underlying infection or thyroid
0.1%–0.2% of patients
treated with ACE inhibitors
Not associated with urticaria
Does not cause anaphylaxis
Usually affects the head and
neck, and may cause lifethreatening respiratory tract
obstruction
Can occur years after the
start of treatment
disease
Investigations Specic IgE tests or skin-
prick tests
Specic IgE tests and skinprick tests often negative
Hypothyroidism should be
Complement C4 (invariably
low in acute attacks)
C1 inhibitor levels
No specic investigations
excluded
Treatment Allergen avoidance
Antihistamines
Associated drug reactions Specic drug allergies NSAIDs
Antihistamines are mainstay
of treatment and prophylaxis
Unresponsive to
antihistamines
Anabolic steroids
C1 inhibitor concentrate or
icatibant for acute attacks
ACE inhibitor should be
discontinued
ARBs should be avoided if
possible unless there is a
strong indication
ACE inhibitors, ARBs
Opioids, radiocontrast media
(ACE = angiotensin-converting enzyme; ARBs = angiotensin II receptor blockers; IgE = immunoglobulin E; NSAIDs = non-steroidal anti-inammatory drugs)
4
exposure can give clues to the underlying diagnosis. If no obvious trigger
can be identied, measurement of complement C4 is useful in differentiating hereditary and acquired angioedema from other causes. If C4 levels
are low, further investigations should be initiated to look for evidence of
C1 inhibitor deciency.
Management
Management depends on the underlying cause. Angioedema associated
with allergen exposure generally responds to antihistamines and glucocorticoids. Following acute management of angioedema secondary to
drug therapy, drug withdrawal should prevent further attacks, although
ACE inhibitor-induced angioedema can continue for a limited period post
drug withdrawal. Management of angioedema associated with C1 inhibitor deciency is discussed below.
Hereditary angioedema
Hereditary angioedema (HAE), also known as inherited C1 inhibitor deciency, is an autosomal dominant disorder caused by decreased production or activity of C1 inhibitor protein. This complement regulatory protein
inhibits spontaneous activation of the classical complement pathway (see
Fig. 4.4). It also acts as an inhibitor of the kinin cascade, activation of which
increases local bradykinin levels, giving rise to local pain and swelling.
Clinical features
The angioedema in HAE may be spontaneous or triggered by local
trauma or infection. Multiple parts of the body may be involved, especially
the face, extremities, upper airway and gastrointestinal tract. Oedema of
the intestinal wall causes severe abdominal pain and many patients with
undiagnosed HAE undergo exploratory laparotomy. The most important
complication is laryngeal obstruction, often associated with minor dental
procedures, which can be fatal. Episodes of angioedema are self-limiting
BA
Fig. 4.15 Angioedema.
From Helbert M. Flesh and bones of
immunology. Edinburgh: Churchill Livingstone, Elsevier Ltd; 2006.
and usually resolve within 48 hours. Patients with HAE generally present
in adolescence but may go undiagnosed for many years. A family history
can be identied in 80% of cases. HAE is not associated with allergic
diseases and is specically not associated with urticaria.
Investigations
Acute episodes are accompanied by low C4 levels; a low C4 during an
episode of angioedema should therefore trigger further investigation. The
diagnosis can be conrmed by measurement of C1 inhibitor levels and
function.
Management
Severe acute attacks should be treated with plasma-derived or recombinant C1 inhibitor or the bradykinin receptor antagonist icatibant. Anabolic
84 C LIN I CA L IM M UN O LOG Y
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
steroids, such as danazol, can be used to prevent attacks and act by
increasing endogenous production of complement proteins, but is limited
by treatment toxicity. Tranexamic acid can be helpful as prophylaxis in
some patients. C1 inhibitor concentrate can also be used as prophylaxis,
for example for surgical or dental intervention. Patients can be taught to
self-administer therapy and should be advised to carry a MedicAlert or
similar. More recently, a humanised monoclonal antibody which inhibits
plasma kallikrein activity, limiting the production of bradykinin, has been
developed for the prevention of recurrent attacks in patients with C1
inhibitor deciency. This is not licensed for acute attacks.
Acquired C1 inhibitor deciency
This rare disorder is clinically indistinguishable from HAE but presents
in late adulthood. It is associated with autoimmune and lymphoproliferative diseases. Most cases are due to the development of autoantibodies to C1 inhibitor, but the condition can also be caused by
autoantibodies that activate C1. Treatment of the underlying disorder
may induce remission of angioedema. As with HAE, a low C4 is seen
during acute episodes.
Pregnancy and the immune system
Major adaptations occur in the immune system during pregnancy so
that the mother does not mount an immune response to the developing
fetus. These adaptations can inuence the risk and severity of certain
infectious diseases such as varicella pneumonia (see p. 1271) as well
as the activity of some autoimmune diseases. Some considerations for
4.19 Immunological diseases in pregnancy
Allergic disease
Maternal dietary restrictions during pregnancy or lactation: current
evidence does not support these for prevention of allergic disease.
Breastfeeding for at least 4 months: prevents or delays the occurrence
of atopic dermatitis, cow's milk allergy and wheezing in early childhood, as
compared with feeding formula milk containing intact cow's milk protein.
Autoimmune disease
Suppressed T-cell-mediated immune responses in pregnancy: may suddenly
reactivate post-partum. Some autoimmune diseases may improve during pregnancy
but are immediately after delivery. Systemic lupus erythematosus (SLE) is an
exception, however, as it is prone to exacerbation in pregnancy or the puerperium.
Passive transfer of maternal antibodies: can mediate autoimmune disease in
the fetus and newborn, including SLE, Graves' disease and myasthenia gravis.
Antiphospholipid syndrome (p. 987): an important cause of fetal loss,
intrauterine growth restriction and pre-eclampsia.
HIV in pregnancy: see p. 367.
the development and management of immunological diseases during
pregnancy and breastfeeding are summarised in Box 4.19
Transplantation and graft rejection
Transplantation provides the opportunity for denitive treatment of endstage organ disease. The major complications are graft rejection, drug
toxicity and infection consequent to immunosuppression. Transplant
survival continues to improve, as a result of the introduction of less toxic
immunosuppressive agents and increased understanding of the processes of transplant rejection. Stem cell transplantation and its complications are discussed in more detail in Chapter 25
Transplant rejection
Solid organ transplantation inevitably stimulates an aggressive immune
response by the recipient, unless the transplant is between monozygotic
twins. The type and severity of the rejection response is determined by
the genetic disparity between the donor and recipient, the immune status of the host and the nature of the tissue transplanted (Box 4.20). The
most important genetic determinant is the difference between donor and
recipient HLA proteins. The extensive polymorphism of these proteins
means that donor HLA antigens are almost invariably recognised as foreign by the recipient immune system, unless an active attempt has been
made to minimise incompatibility.
Hyperacute rejection results in rapid and irreversible destruction
of the graft (see Box 4.20). It is mediated by pre-existing recipient
antibodies against donor HLA antigens, which arise as a result of
previous exposure through transplantation, blood transfusion or
pregnancy. It is very rarely seen in clinical practice, as the use of
screening for anti-HLA antibodies and pre-transplant cross-matching ensures the prior identication of such recipient–donor
incompatibility.
Acute cellular rejection is the most common form of graft rejection. It
is mediated by activated T lymphocytes and results in deterioration
in graft function. If allowed to progress, it may cause fever, pain and
tenderness over the graft. It is usually amenable to increased immunosuppressive therapy.
Acute vascular rejection is mediated by antibody formed de novo
after transplantation. It is more curtailed than the hyperacute
response because of the use of intercurrent immunosuppression but
it is also associated with reduced graft survival. Aggressive immunosuppressive therapy is indicated and physical removal of antibody
through plasmapheresis may be indicated in severe causes. Not
all post-transplant anti-donor antibodies cause graft damage; their
consequences are determined by specicity and ability to trigger
other immune components, such as the complement cascade.
4.20 Classication of transplant rejection
Type Time Pathological ndings Mechanism Treatment
Hyperacute rejection Minutes to hours Thrombosis, necrosis Pre-formed antibody to
Acute cellular rejection 5–30 days Cellular inltration
Acute vascular rejection 5–30 days Vasculitis Antibody and complement
Chronic allograft failure
> 30 days
Fibrosis, scarring Immune and non-immune
donor antigens results in
complement activation (type II
hypersensitivity)
CD4
+
and CD8
+
T cells (type
IV hypersensitivity)
activation
mechanisms
None – irreversible graft loss
Increase immunosuppression
Increase immunosuppression
Minimise drug toxicity,
control hypertension and
hyperlipidaemia
Tumour immu nolog y 85
4.21 Immunosuppressive drugs used in transplantation
Drug Mechanism of action Major adverse effects
Anti-proliferative
agents
Azathioprine,
mycophenolate mofetil
Inhibit lymphocyte
proliferation by
blocking DNA synthesis
May be directly
Increased susceptibility
to infection
Leucopenia
Hepatotoxicity
cytotoxic at high doses
Calcineurin inhibitors
Ciclosporin, tacrolimus
Inhibit T-cell signalling;
prevent lymphocyte
activation; block
cytokine transcription
Increased susceptibility
to infection
Hypertension
Nephrotoxicity
Diabetogenic
(especially tacrolimus)
Gingival hypertrophy,
hirsutism (ciclosporin)
Glucocorticoids Decrease phagocytosis
and release of
proteolytic enzymes;
decrease lymphocyte
Increased susceptibility
to infection
Multiple other
complications
activation and
proliferation; decrease
cytokine production;
decrease antibody
production
Anti-thymocyte
globulin (ATG)
Antibodies to cell
surface proteins
deplete or block T cells
Profound non-specic
immunosuppression
Increased susceptibility
to infection
Basiliximab Monoclonal antibody
directed against
CD25 (IL-2Rα chain),
expressed on activated
Increased susceptibility
to infection
Gastrointestinal side-
effects
T cells
Belatacept Selectively inhibits
T-cell activation
through blockade of
CD80/CD86
Increased susceptibility
to infection and
malignancy
Gastrointestinal side-
effects
Hypertension
Anaemia/leucopenia
classical complement pathway and provides evidence of antibody-mediated damage. This is useful in the early diagnosis of vascular rejection.
Complications of transplant immunosuppression
Transplant recipients require indenite treatment with immunosuppressive agents. In general, two or more immunosuppressive drugs are
used in synergistic combination in order to minimise adverse effects
(Box 4.21). The major complications of long-term immunosuppression
are infection and malignancy. The risk of some opportunistic infections
may be minimised through the use of prophylactic medication, such as
ganciclovir for cytomegalovirus prophylaxis and trimethoprim–sulfamethoxazole for Pneumocystis prophylaxis. Immunisation with killed vaccines
is appropriate, although the immune response may be curtailed. Live
vaccines should not be given.
The increased risk of malignancy arises because T-cell suppression
results in failure to control viral infections associated with malignant
transformation. Virus-associated tumours include lymphoma (associated
with Epstein–Barr virus), Kaposi's sarcoma (associated with human herpesvirus 8) and skin tumours (associated with human papillomavirus).
Immunosuppression is also linked with a small increase in the incidence
of common cancers not associated with viral infection (such as lung,
breast and colon cancer), reecting the importance of T cells in anti-cancer surveillance.
Organ donation
The major problem in transplantation is the shortage of organ donors.
Cadaveric organ donors are usually previously healthy individuals who
experience brainstem death, frequently as a result of road trafc accidents or cerebrovascular events. Even if organs were obtained from all
potential cadaveric donors, though, their numbers would be insufcient
to meet current demands. An alternative is the use of living donors.
Altruistic living donation, usually from close relatives, is widely used in
renal transplantation. Living organ donation is inevitably associated with
some risk to the donor and it is highly regulated to ensure appropriate
appreciation of the risks involved. Because of concerns about coercion
and exploitation, non-altruistic organ donation (the sale of organs) is illegal in most countries.
Tumour immunology
4
Chronic allograft failure, also known as chronic rejection, is a major
cause of graft loss. It is associated with proliferation of transplant
vascular smooth muscle, interstitial brosis and scarring. The
pathogenesis is poorly understood but contributing factors include
immunological damage caused by subacute rejection, hypertension,
hyperlipidaemia and chronic drug toxicity.
Investigations
Pre-transplantation testing
HLA typing determines an individual's HLA polymorphisms and facilitates donor–recipient matching. Potential transplant recipients are also
screened for the presence of anti-HLA antibodies. The recipient is
excluded from receiving a transplant that carries these alleles.
Donor–recipient cross-matching is a functional assay that directly
tests whether serum from a recipient (which potentially contains anti-donor antibodies) is able to bind and/or kill donor lymphocytes. It is specic
to a prospective donor–recipient pair and is done immediately prior to
transplantation. A positive cross-match is a contraindication to transplantation because of the risk of hyperacute rejection.
Post-transplant biopsy: C4d staining
C4d is a fragment of the complement protein C4 (see Fig. 4.4).
Deposition of C4d in graft capillaries indicates local activation of the
Surveillance by the immune system is critically important in monitoring and removing damaged and mutated cells as they arise. The ability of the immune system to kill cancer cells effectively is inuenced
by tumour immunogenicity and specicity. Many cancer antigens are
poorly expressed and specic antigens can mutate, either spontaneously or in response to treatment, which can result in evasion of
immune responses. In addition, the inhibitory pathways that are used
to maintain self-tolerance and limit collateral tissue damage during antimicrobial immune responses can be co-opted by cancerous cells to
evade immune destruction. Recognition and understanding of these
immune checkpoint pathways has led to the development of a number
of new treatments for cancers that are otherwise refractory to treatment. Immune checkpoint blockade enhances anti-tumour immunity
by blocking down-regulators of immune activation. Immune checkpoint inhibitors targeting CTLA-4, PD1 and PD-L1, such as ipilimimab,
nivolumab, and pembrolizumab, have shown benet in a number of
tumour types, including melanoma, non-small cell lung cancer, urothelial cancers, colorectal malignancy and classic Hodgkin’s lymphoma.
These agents can, however, have serious inammatory side effects,
with immune-related adverse events most commonly involving the
skin, liver, endocrine and gastrointestinal tracts, which may be treatment limiting. The effects of the different agents vary, with lung and
thyroid involvement being more common with anti-PD1 therapy, colitis
and hypophysitis being more common with anti-CTLA-4 therapy, with
86 C LIN I CA L IM M UN O LOG Y
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
anti-CTLA-4 therapy-related events often being more severe. However,
patients who have had a favourable response to immune checkpoint
blockade but discontinue as a result of immune-related adverse events
may maintain their anti-tumour response. Glucocorticoids are considered rst line therapy for these side effects, with additional immune
suppression if required. The development of autoimmunity reects the
importance of these pathways in the control of self-tolerance.
Another recent advance is CAR-T cell therapy, in which genetically
engineered, chimaeric antigen receptor T cells are specically developed
for an individual patient, with effective reprogramming of the patient’s
immune cells, which are then used to target their cancer. This has been
applied to certain otherwise treatment-refractory haematological malignancies (Ch. 25). Not only is it a very expensive treatment, but cytokine
storm and subsequent antibody deciency are predictable side effects of
the CAR T-cell therapies directed at B-cell antigens, requiring management in their own right.
Further information
Websites
allergy.org.au An Australasian site providing information on allergy, asthma and
immune diseases.
allergyuk.org UK site for patients and health-care professionals .
anaphylaxis.org.uk Provides information and support for patients with severe
allergies.
info4pi.org A US site managed by the non-prot Jeffrey Modell Foundation, which
provides extensive information about primary immune deciencies .
niaid.nih.gov National Institute of Allergy and Infectious Diseases: provides useful
information on a variety of allergic diseases, immune deciency syndromes and
autoimmune diseases.
Соседние файлы в папке Библиотека им академика М.И. Перельмана